Background: The assessment of potential benefits and harms of a medical procedure is essential for both physicians and patients to make an informed choice among treatment options. There is a paucity of studies on the role of creatine kinase-MB (CKMB) in the prediction of patient outcome after elective percutaneous intervention
Objectives: The current study aimed to assess the association of CKMB level with demographic characteristics and major adverse cardiac events (MACES) after percutaneous coronary intervention (PCI) with drug-eluting stent implantation.
Methods: The study was conducted based on the data concerning the consecutive patients hospitalized for PCI and followed for 12 months. We examined the association between CKMB levels at 12 h post-PCI in patients with drug-eluting stent implantation and demographic characteristics. MACEs were defined as death, myocardial infarction, the need for re-revascularization in the first 48 h after the procedure and during a 1-year follow-up in 2898 patients who underwent PCI in Tehran Heart Center within 2015-2016.
Results: In multivariate logistic regression, after adjustment for differences, no relationship was observed between CKMB level at 12 h post-PCI and 12-month MACEs; nonetheless, in-hospital MACEs were higher in patients who had CKMB> 3 times the upper limit of normal. Furthermore, thrombus, angulated segment, and coronary perforation during the procedure were more prevalent in patients with higher CKMB levels.
Conclusion: The obtained results demonstrated that in patients with elective drug-eluting stent implantation, the moderate elevation of post-procedural CKMB>3 times was associated with in-hospital MACEs. Moreover, no association was found between 1-year adverse events and >3 times the elevation of CKMB.
Sarraf-Zadegan N, Sayed-Tabatabaei F, Bashardoost N, Maleki A, Totonchi M, Habibi H, et al. The prevalence of coronary artery disease in an urban population in Isfahan, Iran. Acta Cardiol. 1999;54(5):257-63. [PubMed: 10596304].
Sellgren A, Nilsson F, Jeppsson A. The relationship between ASAT, CKMB, troponin-T and mortality after cardiac surgery. Scand Cardiovasc J. 2007;41(6):386-90. doi: 10.1080/
14017430701400104. [PubMed: 17852782].
Sá MP, Ferraz PE, Escobar RR, Martins WN, Lustosa PC, Nunes Ede O, et al. Off-pump versus on-pump coronary artery bypass surgery: meta-analysis and meta-regression of 13,524 patients from randomized trials. Rev Braz J Cri Cardiovasc. 2012;
27(4):631-41. doi: 10.5935/1678-9741.20120106. [PubMed: 23515737].
Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase–MB fraction after percutaneous coronary interventions. Circulation. 1996;94(7):1528-36. doi: 10.1161/01.cir.94.7.1528. [PubMed: 8840840].
Kushner FG, Hand M, Smith SC, King SB 3rd, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Catheter Cardiovasc Interv. 2009;54(23):2205-41. doi: 10.1002/ccd.22351. [PubMed: 19924773].
Alhadi HA, Fox KA. Validity of cardiac markers as diagnostic and prognostic indicators of complications in patients undergoing percutaneous coronary intervention. Sultan Qaboos Univ Med J. 2010;10(1):31-40. [PubMed: 21509079].
Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA. 1997;277(6):461-6. [PubMed: 9020269].
Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003;42(8):1406-11. doi: 10.1016/s0735-1097(03)01044-1. [PubMed: 14563583].
Kini AS, Lee P, Marmur JD, Agarwal A, Duffy ME, Kim MC, et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting
mid-term mortality. Am J Cardiol. 2004;93(1):18-23. doi: 10.1016/j.amjcard.2003.09.006. [PubMed: 14697460].
Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation. 2002;106(10):1205-10. doi: 10.1161/01.cir.00000
28146.71416.2e. [PubMed: 12208794].
Stone GW, Mehran R, Dangas G, Lansky AJ, Kornowski R, Leon MB. Differential impact on survival of electrocardiographic
Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation. 2001;104(6):642-7. doi: 10.1161/
hc3101.093902. [PubMed: 11489768].
Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation. 1996;94(7):1528-36. doi: 10.1161/01.cir.94.7.1528. [PubMed: 8840840].
Kugelmass AD, Cohen DJ, Moscucci M, Piana RN, Senerchia C, Kuntz RE, et al. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol. 1994;74(8):748-54. doi: 10.1016/0002-9149(94)90427-8. [PubMed: 7942542].